SMS Pharmaceuticals Limited
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.
What SMS files
- Others61
- Updates24
- Important24
- Investor Meet12
- Pledging11
- Board Meeting8
The Company revised its 38th Annual General Meeting date, altering book closure and dividend record dates. This adjustment, due to administrative constraints, impacts the dividend payout timeline.
SMS Pharma's Q1 revenue rose 6% YoY to ₹207 Cr, with PAT up 8% to ₹20.20 Cr, maintaining 20% EBITDA. Growth was driven by high-value APIs. The ₹280 Cr capex is progressing, alongside a ₹50 Cr investment in peptide R&D for a future product pipeline.
SMS Pharma's board approved Q1 results: Revenue 206.96 Cr, Consolidated Net Profit 20.90 Cr. The MD was re-appointed. They also approved a Rs 50 Cr loan to subsidiary SMS Peptides, pending shareholder nod, and an AGM for dividend eligibility.
SMS Pharma is reminding shareholders about unpaid dividends. Shares linked to 7+ years of unclaimed dividends will be transferred to the Investor Education and Protection Fund. Shareholders should claim their dividends promptly to avoid this transfer, after which they would need to apply to the fund for reclaim.
SMS Pharma: One arrest made in the ongoing police investigation into fraudulent share claims via impersonation. An individual was produced for judicial remand as the company continues to safeguard shareholder interests.